Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Dlk1em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Dlk1em1/Cya

Common Name
Dlk1-KO
Product ID
S-KO-17887
Backgroud
C57BL/6JCya
Strain ID
KOCMP-13386-Dlk1-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Dlk1-KO Mouse (Catalog S-KO-17887) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Dlk1-KO
Strain ID
KOCMP-13386-Dlk1-B6J-VA
Gene Name
Dlk1
Product ID
S-KO-17887
Gene Alias
FA1, ZOG, pG2, DlkI, Peg9, SCP1, DLK-1, Ly107, pref-1
Background
C57BL/6JCya
Gene Full Name
delta like non-canonical Notch ligand 1
Modification
Conventional knockout
NCBI ID
13386 (Mouse)
Phenotype
MGI:94900
Chromosome
Chr 12 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000109844
NCBI Transcript ID
NM_010052
Target Region
Exon 1~5
Size of Effective Region
~7.8 kb
Overview of Gene Research
DLK1, also known as delta-like canonical notch ligand 1, is a maternally imprinted, paternally expressed gene encoding a transmembrane protein. It is a non-canonical NOTCH ligand and plays significant roles in adipose tissue homeostasis, neurogenesis, stem cell pool regulation, and tissue differentiation [1,3]. It is located in the imprinted chromosome 14q32 region, and its deregulation is associated with developmental disorders like Temple syndrome [1,4].

In terms of disease-related findings, paternally inherited genetic defects of DLK1 were identified in families with nonsyndromic central precocious puberty (CPP) and a metabolic phenotype, suggesting its role in modulating the hypothalamic-pituitary-gonadal axis [1]. In neuroblastoma, high expression of DLK1 directly correlates with a super-enhancer, and its silencing leads to increased cellular differentiation. An antibody-drug conjugate targeting DLK1 shows potent cytotoxicity in xenograft models, indicating its potential as an immunotherapeutic target [2]. In adrenocortical carcinoma, DLK1 is a prognostic marker, and its cleavable ectodomain in serum can aid in diagnosis [5]. Also, in hepatocellular carcinoma, DLK1-directed chimeric antigen receptor T-cell therapy can specifically eliminate DLK1-positive cancer cells [6].

In conclusion, DLK1 is crucial for multiple biological processes and is associated with various diseases. Studies on genetic defects and expression patterns in different disease models, such as in CPP, neuroblastoma, adrenocortical carcinoma, and hepatocellular carcinoma, have revealed its significance in disease development and its potential as a therapeutic target. Understanding DLK1 may provide new strategies for treating these diseases.

References:
1. Macedo, Delanie B, Kaiser, Ursula B. 2020. DLK1, Notch Signaling and the Timing of Puberty. In Seminars in reproductive medicine, 37, 174-181. doi:10.1055/s-0039-3400963. https://pubmed.ncbi.nlm.nih.gov/31972862/
2. Hamilton, Amber K, Radaoui, Alexander B, Tsang, Matthew, Maris, John M, Diskin, Sharon J. 2024. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. In Cancer cell, 42, 1970-1982.e7. doi:10.1016/j.ccell.2024.10.003. https://pubmed.ncbi.nlm.nih.gov/39454577/
3. Grassi, Elisa Stellaria, Pietras, Alexander. 2021. Emerging Roles of DLK1 in the Stem Cell Niche and Cancer Stemness. In The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 70, 17-28. doi:10.1369/00221554211048951. https://pubmed.ncbi.nlm.nih.gov/34606325/
4. Enterina, Jhon R, Enfield, Katey S S, Anderson, Christine, Ng, Kevin W, Lam, Wan L. 2017. DLK1-DIO3 imprinted locus deregulation in development, respiratory disease, and cancer. In Expert review of respiratory medicine, 11, 749-761. doi:10.1080/17476348.2017.1355241. https://pubmed.ncbi.nlm.nih.gov/28715922/
5. Mariniello, Katia, Pittaway, James F H, Altieri, Barbara, Fassnacht, Martin, Guasti, Leonardo. 2024. Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. In bioRxiv : the preprint server for biology, , . doi:10.1101/2024.08.22.609117. https://pubmed.ncbi.nlm.nih.gov/39229217/
6. Zhai, Yangyang, He, Kunyan, Huang, Liyu, Yuan, Guandou, Han, Ze-Guang. 2022. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma. In Liver international : official journal of the International Association for the Study of the Liver, 42, 2524-2537. doi:10.1111/liv.15411. https://pubmed.ncbi.nlm.nih.gov/36002393/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research